精华制药(002349) - 2022 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2022 reached ¥383,482,150.04, an increase of 17.08% year-over-year, while total revenue for the year-to-date was ¥1,175,028,595.83, up 21.26% compared to the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥38,794,132.60, a significant increase of 71.48% year-over-year, with year-to-date net profit at ¥168,876,231.79, up 31.52%[7] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥35,717,425.87, a remarkable increase of 457.91% year-over-year, while year-to-date figures showed an increase of 67.38% to ¥156,080,799.46[7] - Basic and diluted earnings per share for Q3 2022 were both ¥0.0476, reflecting a 71.22% increase compared to the same period last year[7] - Total operating revenue for the current period reached ¥1,175,028,595.83, an increase of 21.3% compared to ¥969,008,945.04 in the previous period[27] - Net profit for the current period was ¥189,378,012.57, representing a 55.8% increase from ¥121,591,358.11 in the previous period[30] - Earnings per share (EPS) for the current period was ¥0.2074, compared to ¥0.1577 in the previous period, reflecting a 31.5% increase[32] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥3,193,165,938.79, a slight decrease of 0.15% from the end of the previous year, while equity attributable to shareholders increased by 5.54% to ¥2,359,745,363.70[7] - The total liabilities are reported at ¥466,968,535.87, compared to ¥603,237,286.18 previously[23] - The company's total liabilities decreased to ¥492,014,940.07 from ¥628,539,798.06, indicating a reduction of approximately 21.7%[26] - Total equity attributable to shareholders increased to ¥2,359,745,363.70 from ¥2,235,838,542.50, marking a growth of 5.5%[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥247,371,958.46, representing an increase of 8.27% compared to the same period last year[7] - Cash inflow from operating activities totaled ¥1,210,617,750.13, an increase from ¥1,060,825,645.53 in the previous period[33] - The net cash flow from operating activities was $247,371,958.46, an increase from $228,477,820.16 in the previous period, reflecting a growth of approximately 4%[35] - Total cash inflow from investment activities reached $514,188,001.96, significantly higher than $241,445,648.28 in the prior period, marking an increase of about 113%[35] - The company reported a significant increase in cash received from investment recoveries, totaling $507,142,234.96, compared to $179,576,646.56 in the previous period, indicating a growth of approximately 182%[35] Expenses and Investments - The company reported a significant decrease in financial expenses, which were -¥14,093,562.17 for the year-to-date, a reduction of 1899.88% year-over-year due to increased deposit income and reduced bank loan interest payments[12] - Research and development expenses for the current period were ¥47,557,128.54, down from ¥53,347,000.10 in the previous period, a decrease of 10.8%[27] - The company has a long-term investment in equity amounting to ¥17,402,050.83, down from ¥19,093,016.10[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 152,377[16] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[16] Inventory and Receivables - Accounts receivable increased to ¥275,852,312.81 from ¥213,685,445.94, reflecting a growth of approximately 29%[20] - Inventory as of September 30, 2022, is valued at ¥332,331,582.47, up from ¥323,123,183.77[23]